edoxaban 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
blood coagulation factor XA inhibitors, antithrombotics	4897	480449-70-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: edoxaban tosylate edoxaban edoxaban tosilate edoxaban tosilate hydrate lixiana DU-176b savaysa	An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion. Molecular weight: 548.06 Formula: C24H30ClN7O4S CLOGP: 1.86 LIPINSKI: 2 HAC: 11 HDO: 3 TPSA: 136.63 ALOGS: -4.68 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

edoxaban tosylate
edoxaban
edoxaban tosilate
edoxaban tosilate hydrate
lixiana
DU-176b
savaysa

An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion.

Molecular weight: 548.06
Formula: C24H30ClN7O4S
CLOGP: 1.86
LIPINSKI: 2
HAC: 11
HDO: 3
TPSA: 136.63
ALOGS: -4.68
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	1.53 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.19 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.50 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.70 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.09 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company
June 19, 2015	EMA	Daiichi Sankyo Europe GmbH
Jan. 8, 2015	FDA	DAIICHI SANKYO
April 22, 2011	PMDA	DAIICHI SANKYO COMPANY, Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	275.48	21.04	264	12385	201138	63275235
Anaemia	233.43	21.04	289	12360	293141	63183232
Cardiac failure	182.11	21.04	147	12502	88995	63387378
Labelled drug-drug interaction medication error	142.15	21.04	64	12585	13335	63463038
Melaena	138.03	21.04	82	12567	30283	63446090
Renal impairment	136.13	21.04	124	12525	88231	63388142
Product monitoring error	132.03	21.04	45	12604	4471	63471902
Atrial fibrillation	124.50	21.04	134	12515	116502	63359871
Haematochezia	115.00	21.04	91	12558	53453	63422920
Drug ineffective	103.31	21.04	40	12609	1044725	62431648
Gastrointestinal haemorrhage	96.81	21.04	99	12550	81077	63395296
Arrhythmia	93.19	21.04	70	12579	38070	63438303
Arterial haemorrhage	86.97	21.04	26	12623	1691	63474682
Lymphatic fistula	86.97	21.04	22	12627	764	63475609
Femoral hernia incarcerated	85.49	21.04	22	12627	819	63475554
Cerebral infarction	82.01	21.04	54	12595	23839	63452534
Tachycardia	81.89	21.04	109	12540	118047	63358326
Pancreatic steatosis	81.37	21.04	22	12627	994	63475379
Haematuria	76.80	21.04	56	12593	29101	63447272
Pallor	76.67	21.04	57	12592	30511	63445862
Wound infection pseudomonas	75.54	21.04	22	12627	1306	63475067
Embolic stroke	74.05	21.04	28	12621	3748	63472625
Hyponatraemia	71.12	21.04	99	12550	111801	63364572
Aortic valve stenosis	70.31	21.04	26	12623	3273	63473100
Product prescribing error	68.13	21.04	50	12599	26239	63450134
Seroma	65.29	21.04	22	12627	2109	63474264
Haemarthrosis	64.02	21.04	24	12625	3137	63473236
Tachyarrhythmia	62.75	21.04	26	12623	4424	63471949
Hyperkalaemia	60.80	21.04	64	12585	54139	63422234
Subarachnoid haemorrhage	58.25	21.04	36	12613	14247	63462126
Oedema peripheral	54.48	21.04	118	12531	189393	63286980
Anuria	52.11	21.04	32	12617	12519	63463854
Dyspnoea	51.23	21.04	263	12386	661050	62815323
Eructation	49.99	21.04	27	12622	8306	63468067
Hepatic cyst	49.55	21.04	23	12626	5131	63471242
Systemic infection	48.58	21.04	22	12627	4638	63471735
Faecaloma	48.39	21.04	26	12623	7915	63468458
Wound dehiscence	47.51	21.04	22	12627	4881	63471492
Syncope	46.94	21.04	84	12565	117301	63359072
Diverticulum intestinal	46.65	21.04	24	12625	6689	63469684
Aortic arteriosclerosis	45.48	21.04	23	12626	6186	63470187
Cardiospasm	44.24	21.04	16	12633	1891	63474482
Atrial tachycardia	44.15	21.04	20	12629	4220	63472153
Palmoplantar keratoderma	43.44	21.04	16	12633	1991	63474382
Inflammatory marker increased	43.38	21.04	23	12626	6816	63469557
Bradycardia	42.38	21.04	62	12587	73165	63403208
Therapeutic drug monitoring analysis not performed	41.59	21.04	14	12635	1338	63475035
Hypersensitivity	41.14	21.04	5	12644	292680	63183693
Shock haemorrhagic	40.50	21.04	25	12624	9870	63466503
Drug hypersensitivity	39.76	21.04	7	12642	310680	63165693
Cerebral haemorrhage	39.38	21.04	39	12610	30690	63445683
Pruritus genital	39.10	21.04	16	12633	2638	63473735
Sleep terror	38.94	21.04	16	12633	2664	63473709
Joint swelling	38.57	21.04	9	12640	327657	63148716
Infusion related reaction	37.63	21.04	3	12646	245518	63230855
Internal haemorrhage	37.44	21.04	19	12630	5146	63471227
Groin pain	37.30	21.04	24	12625	10179	63466194
Drug intolerance	37.29	21.04	8	12641	308653	63167720
Thrombophlebitis migrans	37.19	21.04	8	12641	134	63476239
Escherichia infection	37.03	21.04	26	12623	12728	63463645
Cardiovascular disorder	36.45	21.04	25	12624	11787	63464586
Aplastic anaemia	36.20	21.04	23	12626	9546	63466827
Tricuspid valve incompetence	36.06	21.04	27	12622	14594	63461779
Myelodysplastic syndrome	34.91	21.04	28	12621	16726	63459647
Rheumatoid arthritis	34.08	21.04	5	12644	253814	63222559
Left ventricular dysfunction	33.79	21.04	24	12625	11964	63464409
Acute kidney injury	33.59	21.04	122	12527	263293	63213080
Postoperative wound infection	33.42	21.04	23	12626	10902	63465471
Mitral valve incompetence	33.08	21.04	29	12620	19565	63456808
Product dose omission issue	32.93	21.04	4	12645	234309	63242064
Angina pectoris	32.80	21.04	35	12614	30043	63446330
BRASH syndrome	32.21	21.04	9	12640	460	63475913
Electrocardiogram abnormal	32.10	21.04	21	12628	9158	63467215
Pain	32.09	21.04	62	12587	740566	62735807
Chorea	31.69	21.04	12	12637	1612	63474761
Tension headache	31.65	21.04	17	12632	5169	63471204
Sinusitis	31.53	21.04	4	12645	226649	63249724
Ischaemic stroke	31.17	21.04	27	12622	17930	63458443
Carotid artery occlusion	30.38	21.04	16	12633	4678	63471695
Hypokalaemia	30.20	21.04	65	12584	103739	63372634
Blindness	28.66	21.04	28	12621	21671	63454702
Haematoma	28.61	21.04	35	12614	34785	63441588
Psychotic symptom	28.54	21.04	11	12638	1550	63474823
Hepatic function abnormal	28.39	21.04	36	12613	37106	63439267
Nasopharyngitis	27.96	21.04	8	12641	254249	63222124
Drug interaction	27.42	21.04	104	12545	229027	63247346
Cardiogenic shock	27.23	21.04	25	12624	17907	63458466
Rhonchi	26.34	21.04	12	12637	2564	63473809
Swelling	26.26	21.04	11	12638	275367	63201006
Streptococcal sepsis	26.19	21.04	11	12638	1935	63474438
Dehydration	26.19	21.04	85	12564	173269	63303104
Product use issue	26.05	21.04	6	12643	220514	63255859
Gastroenteritis clostridial	25.86	21.04	8	12641	584	63475789
Pulmonary hypertension	25.29	21.04	34	12615	37089	63439284
Anosmia	24.74	21.04	16	12633	6844	63469529
Pseudomonal sepsis	23.97	21.04	11	12638	2390	63473983
Immunisation	23.95	21.04	9	12640	1184	63475189
Decreased appetite	23.76	21.04	106	12543	250946	63225427
Oesophageal mucosal tear	23.46	21.04	4	12645	17	63476356
Osteopenia	23.31	21.04	24	12625	19761	63456612
Electrolyte imbalance	23.02	21.04	24	12625	20052	63456321
Joint dislocation	22.50	21.04	23	12626	18777	63457596
Product used for unknown indication	22.44	21.04	7	12642	525	63475848
Subdural haematoma	21.80	21.04	20	12629	14308	63462065
Sopor	21.06	21.04	24	12625	22140	63454233

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	148.88	18.37	187	10251	128082	34818411
Renal impairment	141.46	18.37	157	10281	94356	34852137
Anaemia	139.37	18.37	249	10189	233086	34713407
Cerebral infarction	131.76	18.37	89	10349	27366	34919127
Haematuria	116.98	18.37	106	10332	49960	34896533
Cardiac failure	102.47	18.37	131	10307	91117	34855376
Atrial fibrillation	97.56	18.37	149	10289	122244	34824249
Melaena	94.80	18.37	81	10357	35299	34911194
Product monitoring error	88.04	18.37	37	10401	4344	34942149
Pelvic mass	87.67	18.37	19	10419	214	34946279
Embolic stroke	67.99	18.37	31	10407	4423	34942070
Blood urea abnormal	64.22	18.37	19	10419	789	34945704
Prostate cancer recurrent	64.15	18.37	20	10418	993	34945500
Malignant transformation	63.25	18.37	19	10419	832	34945661
Blood electrolytes abnormal	60.83	18.37	19	10419	949	34945544
Systemic infection	57.42	18.37	29	10409	5183	34941310
Interstitial lung disease	54.05	18.37	81	10357	65201	34881292
Drug ineffective	52.92	18.37	36	10402	456715	34489778
Haematochezia	50.86	18.37	66	10372	46468	34900025
Epistaxis	49.25	18.37	73	10365	58178	34888315
Oedema peripheral	48.47	18.37	109	10329	119703	34826790
Respiratory tract haemorrhage	48.04	18.37	17	10421	1253	34945240
Cerebral haemorrhage	43.67	18.37	53	10385	34884	34911609
Dyspnoea	43.37	18.37	224	10214	376558	34569935
Urogenital haemorrhage	40.11	18.37	13	10425	732	34945761
Labelled drug-drug interaction medication error	39.56	18.37	34	10404	14905	34931588
Dysuria	38.59	18.37	44	10394	27108	34919385
Gastrointestinal haemorrhage	38.59	18.37	83	10355	88394	34858099
Fluid intake reduced	36.17	18.37	19	10419	3682	34942811
Electrocardiogram abnormal	35.09	18.37	26	10412	9221	34937272
Cardiac amyloidosis	33.53	18.37	13	10425	1238	34945255
Product prescribing error	32.32	18.37	37	10401	22890	34923603
Upper gastrointestinal haemorrhage	30.73	18.37	38	10400	25480	34921013
Subdural haematoma	30.56	18.37	34	10404	20387	34926106
Pallor	29.17	18.37	37	10401	25443	34921050
Shock haemorrhagic	28.36	18.37	25	10413	11329	34935164
Hydronephrosis	28.31	18.37	24	10414	10322	34936171
Haemorrhage	28.12	18.37	53	10385	51317	34895176
Procedural failure	27.73	18.37	6	10432	67	34946426
Cardiac failure chronic	27.34	18.37	21	10417	7858	34938635
Pseudarthrosis	27.11	18.37	6	10432	75	34946418
Drug interaction	27.03	18.37	136	10302	225810	34720683
Pulmonary alveolar haemorrhage	26.02	18.37	20	10418	7492	34939001
Product dose omission issue	25.36	18.37	3	10435	119708	34826785
Medication error	24.46	18.37	34	10404	25531	34920962
Tracheal pain	24.09	18.37	5	10433	45	34946448
Peri-implantitis	23.93	18.37	6	10432	132	34946361
Haematoma	22.94	18.37	33	10405	25572	34920921
Haemoptysis	21.54	18.37	38	10400	34968	34911525
Duodenal ulcer haemorrhage	21.08	18.37	15	10423	4998	34941495
Haematemesis	20.95	18.37	33	10405	27678	34918815
Gastric haemorrhage	20.60	18.37	20	10418	10241	34936252
Dehydration	20.55	18.37	85	10353	129884	34816609
Stress urinary incontinence	20.44	18.37	5	10433	99	34946394
Cardiac tamponade	20.41	18.37	15	10423	5251	34941242
Toxicity to various agents	20.29	18.37	18	10420	200344	34746149
Haemothorax	19.68	18.37	13	10425	3839	34942654
Syncope	19.63	18.37	66	10372	91385	34855108
Phrenic nerve paralysis	19.57	18.37	5	10433	119	34946374
Documented hypersensitivity to administered product	19.18	18.37	6	10432	301	34946192
Heart rate	19.07	18.37	4	10434	38	34946455
Pneumonia aspiration	19.04	18.37	40	10398	41863	34904630
Therapeutic drug monitoring analysis incorrectly performed	18.79	18.37	6	10432	322	34946171
Thalamus haemorrhage	18.57	18.37	8	10430	997	34945496
Sinus node dysfunction	18.53	18.37	13	10425	4236	34942257
Endoscopy upper gastrointestinal tract	18.46	18.37	4	10434	45	34946448

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	410.64	16.53	441	21748	274797	79447402
Anaemia	352.13	16.53	519	21670	444496	79277703
Renal impairment	274.68	16.53	275	21914	157508	79564691
Cardiac failure	251.50	16.53	260	21929	154582	79567617
Cerebral infarction	213.80	16.53	142	22047	45534	79676665
Melaena	209.93	16.53	157	22032	60733	79661466
Atrial fibrillation	209.03	16.53	266	21923	197620	79524579
Product monitoring error	207.56	16.53	82	22107	8824	79713375
Haematuria	182.40	16.53	152	22037	68684	79653515
Labelled drug-drug interaction medication error	159.25	16.53	98	22091	27552	79694647
Haematochezia	154.57	16.53	154	22035	87491	79634708
Drug ineffective	131.41	16.53	69	22120	1080844	78641355
Embolic stroke	128.08	16.53	56	22133	7770	79714429
Gastrointestinal haemorrhage	118.58	16.53	174	22015	147545	79574654
Systemic infection	101.38	16.53	51	22138	9701	79712498
Oedema peripheral	100.86	16.53	219	21970	252069	79470130
Pallor	93.86	16.53	91	22098	49971	79672228
Product prescribing error	92.66	16.53	86	22103	44727	79677472
Dyspnoea	88.59	16.53	470	21719	856555	78865644
Cerebral haemorrhage	79.63	16.53	89	22100	57584	79664615
Arterial haemorrhage	79.21	16.53	29	22160	2532	79719667
Lymphatic fistula	79.21	16.53	22	22167	781	79721418
Femoral hernia incarcerated	78.17	16.53	22	22167	820	79721379
Tachycardia	77.57	16.53	160	22029	177608	79544591
Arrhythmia	71.95	16.53	87	22102	61185	79661014
Pancreatic steatosis	71.50	16.53	22	22167	1123	79721076
Interstitial lung disease	71.31	16.53	119	22070	112481	79609718
Prostate cancer recurrent	69.75	16.53	20	22169	798	79721401
Electrocardiogram abnormal	66.35	16.53	47	22142	16690	79705509
Shock haemorrhagic	65.25	16.53	50	22139	20010	79702189
Wound infection pseudomonas	63.98	16.53	22	22167	1599	79720600
Aortic valve stenosis	58.91	16.53	29	22160	5265	79716934
Syncope	58.65	16.53	144	22045	179305	79542894
Malignant transformation	57.85	16.53	19	22170	1199	79721000
Pelvic mass	57.83	16.53	19	22170	1200	79720999
Dysuria	57.63	16.53	71	22118	50880	79671319
Seroma	56.47	16.53	22	22167	2278	79719921
Blood urea abnormal	56.25	16.53	19	22170	1308	79720891
Drug intolerance	55.16	16.53	5	22184	264114	79458085
Tachyarrhythmia	54.15	16.53	30	22159	6932	79715267
Subdural haematoma	51.28	16.53	53	22136	31381	79690818
Product dose omission issue	50.86	16.53	5	22184	247532	79474667
Blood electrolytes abnormal	49.26	16.53	19	22170	1915	79720284
Haemarthrosis	47.84	16.53	26	22163	5786	79716413
Bradycardia	47.74	16.53	112	22077	135445	79586754
Thrombophlebitis migrans	47.57	16.53	13	22176	434	79721765
Drug hypersensitivity	46.16	16.53	13	22176	298903	79423296
Dehydration	44.53	16.53	161	22028	248026	79474173
Angina pectoris	44.45	16.53	63	22126	51669	79670530
Respiratory tract haemorrhage	43.22	16.53	17	22172	1806	79720393
Nasopharyngitis	43.19	16.53	9	22180	253872	79468327
Upper gastrointestinal haemorrhage	42.56	16.53	55	22134	41325	79680874
Urogenital haemorrhage	41.46	16.53	14	22175	963	79721236
Hepatic cyst	41.33	16.53	24	22165	6065	79716134
Diverticulum intestinal	40.82	16.53	27	22162	8578	79713621
Rheumatoid arthritis	40.82	16.53	5	22184	208465	79513734
Internal haemorrhage	40.18	16.53	27	22162	8806	79713393
Sinusitis	40.02	16.53	4	22185	195497	79526702
Cardiac failure chronic	38.97	16.53	29	22160	11106	79711093
Toxicity to various agents	38.92	16.53	36	22153	421504	79300695
Haematoma	38.27	16.53	59	22130	52136	79670063
Hyperkalaemia	37.56	16.53	92	22097	114306	79607893
Infusion related reaction	37.47	16.53	9	22180	230228	79491971
Hypersensitivity	35.93	16.53	14	22175	262225	79459974
Therapeutic drug monitoring analysis not performed	35.44	16.53	15	22174	1921	79720278
Arthropathy	35.28	16.53	4	22185	177107	79545092
Gastric haemorrhage	35.26	16.53	31	22158	15019	79707180
Aortic arteriosclerosis	35.24	16.53	25	22164	8893	79713306
Eructation	35.06	16.53	27	22162	10882	79711317
Hyponatraemia	35.01	16.53	119	22070	177729	79544470
Musculoskeletal stiffness	34.74	16.53	4	22185	175004	79547195
Wound dehiscence	34.49	16.53	22	22167	6573	79715626
Ischaemic stroke	34.02	16.53	44	22145	33087	79689112
Hydronephrosis	33.21	16.53	32	22157	17422	79704777
Groin pain	32.78	16.53	28	22161	13052	79709147
Epistaxis	32.77	16.53	86	22103	111429	79610770
Joint swelling	32.59	16.53	20	22169	288626	79433573
Putamen haemorrhage	32.56	16.53	10	22179	507	79721692
Subarachnoid haemorrhage	32.47	16.53	37	22152	24428	79697771
Cardiovascular disorder	32.33	16.53	32	22157	17993	79704206
Drug interaction	31.83	16.53	211	21978	414972	79307227
Pulmonary alveolar haemorrhage	31.77	16.53	26	22163	11431	79710768
Thirst	31.46	16.53	32	22157	18587	79703612
Synovitis	31.06	16.53	3	22186	150731	79571468
Endocarditis noninfective	30.66	16.53	8	22181	223	79721976
Colon cancer	30.25	16.53	28	22161	14495	79707704
Pain	30.21	16.53	98	22091	703704	79018495
Anuria	30.04	16.53	33	22156	20930	79701269
Cardiac amyloidosis	29.56	16.53	13	22176	1827	79720372
BRASH syndrome	29.55	16.53	11	22178	1006	79721193
Faecaloma	29.48	16.53	25	22164	11539	79710660
Decreased appetite	29.31	16.53	179	22010	342239	79379960
Medication error	28.97	16.53	61	22128	68581	79653618
Electrolyte imbalance	28.61	16.53	39	22150	30842	79691357
Haemorrhage	28.55	16.53	72	22117	91046	79631153
Product used for unknown indication	28.39	16.53	12	22177	1532	79720667
Atrial tachycardia	28.20	16.53	20	22169	7113	79715086
Pneumonia aspiration	27.67	16.53	59	22130	66908	79655291
Haemorrhage subcutaneous	27.56	16.53	17	22172	4792	79717407
Haemoptysis	27.50	16.53	53	22136	55946	79666253
Depression	27.42	16.53	13	22176	216777	79505422
Swelling	27.40	16.53	13	22176	216698	79505501
Postoperative wound infection	27.02	16.53	25	22164	12936	79709263
Inflammatory marker increased	26.94	16.53	23	22166	10717	79711482
Procedural failure	26.90	16.53	6	22183	84	79722115
Tricuspid valve incompetence	26.47	16.53	30	22159	19682	79702517
Acute kidney injury	26.46	16.53	240	21949	519164	79203035
Chorea	26.18	16.53	13	22176	2404	79719795
Product use issue	25.90	16.53	13	22176	209809	79512390
Fluid intake reduced	25.71	16.53	18	22171	6270	79715929
Injection site pain	25.69	16.53	3	22186	129835	79592364
Haemothorax	25.53	16.53	17	22172	5461	79716738
Hepatic function abnormal	25.28	16.53	60	22129	73047	79649152
Treatment failure	25.23	16.53	8	22181	170478	79551721
Left ventricular dysfunction	25.21	16.53	29	22160	19332	79702867
Arthralgia	24.94	16.53	79	22110	571724	79150475
Mitral valve incompetence	24.85	16.53	35	22154	28530	79693669
Carotid artery occlusion	24.73	16.53	19	22170	7628	79714571
Discomfort	24.61	16.53	3	22186	125614	79596585
Tracheal pain	24.44	16.53	5	22184	45	79722154
Endoscopy upper gastrointestinal tract	24.05	16.53	6	22183	139	79722060
Vertebrobasilar insufficiency	23.84	16.53	7	22182	304	79721895
Thalamus haemorrhage	23.59	16.53	11	22178	1771	79720428
Urticaria	23.58	16.53	11	22178	185190	79537009
Haematemesis	22.70	16.53	47	22142	52217	79669982
Oesophageal mucosal tear	22.52	16.53	4	22185	15	79722184
Sinus node dysfunction	22.46	16.53	18	22171	7683	79714516
Cardiospasm	22.37	16.53	13	22176	3288	79718911
Anticoagulant-related nephropathy	22.29	16.53	5	22184	72	79722127
Psychotic symptom	22.02	16.53	12	22177	2685	79719514
Anxiety	22.00	16.53	22	22167	248490	79473709
Escherichia infection	21.82	16.53	26	22163	17991	79704208
Tachypnoea	21.78	16.53	35	22154	32028	79690171
Peri-implantitis	21.65	16.53	6	22183	211	79721988
Schizoaffective disorder	21.62	16.53	11	22178	2141	79720058
Duodenal ulcer haemorrhage	21.44	16.53	17	22172	7146	79715053
Anticoagulation drug level increased	21.17	16.53	8	22181	763	79721436
Palmoplantar keratoderma	20.95	16.53	13	22176	3703	79718496
Palpitations	20.89	16.53	80	22109	126530	79595669
Aplastic anaemia	20.32	16.53	25	22164	17880	79704319
Haemobilia	20.20	16.53	7	22182	521	79721678
Headache	19.90	16.53	104	22085	653668	79068531
Alopecia	19.89	16.53	21	22168	231334	79490865
Intentional overdose	19.64	16.53	3	22186	105957	79616242
Small intestinal haemorrhage	19.60	16.53	13	22176	4150	79718049
Mobility decreased	19.43	16.53	5	22184	122170	79600029
Intentional product use issue	19.42	16.53	9	22180	152103	79570096
Influenza	19.32	16.53	6	22183	129600	79592599
Transient ischaemic attack	19.03	16.53	44	22145	52651	79669548
Marasmus	18.94	16.53	8	22181	1020	79721179
Sleep terror	18.79	16.53	13	22176	4445	79717754
Pruritus genital	18.71	16.53	13	22176	4473	79717726
Faeces discoloured	18.71	16.53	31	22158	29096	79693103
Therapeutic product effect incomplete	18.68	16.53	8	22181	141637	79580562
Muscle spasms	18.50	16.53	13	22176	174717	79547482
Drug eruption	18.48	16.53	39	22150	43896	79678303
Joint dislocation	18.18	16.53	23	22166	16916	79705283
Occult blood	17.87	16.53	9	22180	1714	79720485
Arthritis	17.71	16.53	5	22184	114875	79607324
Diverticulum intestinal haemorrhagic	17.62	16.53	12	22177	3999	79718200
Rhonchi	17.55	16.53	12	22177	4024	79718175
Seizure	17.55	16.53	16	22173	188818	79533381
Hypokalaemia	17.54	16.53	83	22106	143957	79578242
Malignant neoplasm progression	17.03	16.53	79	22110	135911	79586288
Urinary retention	16.96	16.53	44	22145	56586	79665613
Microcytic anaemia	16.83	16.53	13	22176	5261	79716938
Osteopenia	16.72	16.53	23	22166	18341	79703858

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AF03	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Direct factor Xa inhibitors
MeSH PA	D000925	Anticoagulants
MeSH PA	D000991	Antithrombins
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D065427	Factor Xa Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D015842	Serine Proteinase Inhibitors
FDA MoA	N0000175635	Factor Xa Inhibitors
FDA EPC	N0000175637	Factor Xa Inhibitor
CHEBI has role	CHEBI:50249	anticoagulants
CHEBI has role	CHEBI:50427	platelet aggregation inhibitors
CHEBI has role	CHEBI:68581	factor Xa inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pulmonary embolism	indication	59282003	DOID:9477
Embolism	indication	414086009
Ischemic stroke	indication	422504002
Prevention of deep vein thrombosis	indication	439993001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.7	acidic
pKa2	12.4	acidic
pKa3	6.8	Basic
pKa4	3.01	Basic
pKa5	2.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Coagulation factor X	Enzyme	P00742	FA10_HUMAN	INHIBITOR	Ki	9.25		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
D09546	KEGG_DRUG
480449-71-6	SECONDARY_CAS_RN
4034081	VANDF
CHEBI:85974	CHEBI
CHEMBL1269025	ChEMBL_ID
CHEMBL2105682	ChEMBL_ID
C552171	MESH_SUPPLEMENTAL_RECORD_UI
7575	IUPHAR_LIGAND_ID
DB09075	DRUGBANK_ID
1599538	RXNORM
232451	MMSL
30841	MMSL
30865	MMSL
d08338	MMSL
015852	NDDF
015853	NDDF
1162278009	SNOMEDCT_US
712778008	SNOMEDCT_US
714687009	SNOMEDCT_US
C2975435	UMLSCUI
8982	INN_ID
10280735	PUBCHEM_CID
NDU3J18APO	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-201	TABLET, FILM COATED	15 mg	ORAL	NDA	34 sections
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-201	TABLET, FILM COATED	15 mg	ORAL	NDA	34 sections
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-201	TABLET, FILM COATED	15 mg	ORAL	NDA	34 sections
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-202	TABLET, FILM COATED	30 mg	ORAL	NDA	34 sections
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-202	TABLET, FILM COATED	30 mg	ORAL	NDA	34 sections
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-202	TABLET, FILM COATED	30 mg	ORAL	NDA	34 sections
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-203	TABLET, FILM COATED	60 mg	ORAL	NDA	34 sections
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-203	TABLET, FILM COATED	60 mg	ORAL	NDA	34 sections
SAVAYSA	HUMAN PRESCRIPTION DRUG LABEL	1	65597-203	TABLET, FILM COATED	60 mg	ORAL	NDA	34 sections